Catecholaminergic Polymorphic Ventricular Tachycardia — sudden cardiac death during exercise or emotional stress in children and young adults with structurally normal hearts and normal resting ECGs.
RYR2 and CASQ2 are on the ACMG SF v3.2 mandatory secondary findings list. Whole genome sequencing identifies all CPVT-associated genetic variants, enabling treatment that can prevent sudden death before it occurs.
Catecholaminergic Polymorphic Ventricular Tachycardia
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal inherited arrhythmia syndrome characterized by stress-induced ventricular arrhythmias in individuals with structurally normal hearts and normal resting ECGs. During physical exercise or acute emotional stress, catecholamine surges trigger abnormal calcium release from the sarcoplasmic reticulum within cardiac myocytes, producing triggered ventricular ectopy that degenerates into bidirectional or polymorphic ventricular tachycardia and ventricular fibrillation. CPVT affects approximately 1 in 10,000 individuals and is responsible for approximately 15% of unexplained sudden cardiac arrest cases in individuals under 40 with normal hearts.
CPVT is genetically heterogeneous. The most common cause is autosomal dominant pathogenic variants in RYR2 (ryanodine receptor 2), which encodes the cardiac sarcoplasmic reticulum calcium release channel and accounts for approximately 60-70% of CPVT cases (CPVT1). RYR2 is a massive gene with 105 exons and over 300 pathogenic variants documented. Autosomal recessive CPVT (CPVT2) is caused by pathogenic variants in CASQ2 (calsequestrin 2) and accounts for approximately 3-5% of cases. Additional CPVT-associated genes include TRDN (triadin), CALM1, CALM2, CALM3, KCNJ2 (Timothy syndrome-related), and ANK2. The CALM genes are now on the ACMG SF v3.2 list, joining RYR2 and CASQ2 as mandatory secondary findings candidates.
The danger of CPVT lies in its deceptive normalcy at rest. Standard cardiac evaluation — ECG, echocardiogram, and Holter monitoring — is uniformly normal in CPVT patients between episodes. The condition is revealed only by exercise stress testing, which provokes the characteristic bidirectional or polymorphic VT. Many cases are diagnosed only after a child or young adult survives an exercise-induced cardiac arrest, or after a first-degree relative dies suddenly during exercise. Beta-blocker therapy (nadolol preferred) substantially reduces arrhythmia burden. ICD implantation is recommended for survivors of cardiac arrest or in patients with breakthrough arrhythmias on optimal medical therapy. Flecainide provides additional antiarrhythmic benefit in combination with beta-blockers.
CPVT1 (RYR2, autosomal dominant) is the most common form. CPVT2 (CASQ2, autosomal recessive) is rarer and often more severe. CALM1/2/3 variants cause a phenotypically overlapping syndrome with additional QT prolongation.
RYR2 is one of the largest genes in the human genome with 105 exons. Standard CPVT panels sequence RYR2 and CASQ2 but may miss deep intronic variants and rare structural rearrangements in this enormous gene.
RYR2 with 105 exons is one of the most challenging genes to sequence completely — and missed variants have fatal consequences
The RYR2 gene spans over 800 kilobases of genomic DNA with 105 coding exons. Comprehensive RYR2 sequencing is technically demanding, and some gene panel designs use reduced coverage in intronic regions adjacent to hotspot exons. Deep intronic RYR2 variants that create aberrant splice sites have been documented in CPVT patients with initially negative panel results. The clinical consequence of a missed RYR2 variant in CPVT is not an inconvenience — it is an unprotected young person who continues to exercise without diagnosis or treatment, with each vigorous physical activity episode representing a cardiac arrest risk. Whole genome sequencing provides uniform coverage across all 105 RYR2 exons and flanking intronic sequence.
A 'hidden' CPVT diagnosis changes every recommendation — activity, medication, ICD, family cascade testing
Once a CPVT diagnosis is established, management is immediate and comprehensive: beta-blocker therapy (typically nadolol at maximum tolerated dose), activity restriction to avoid vigorous exercise, prohibition of competitive sports, consideration of ICD implantation, and cascade genetic testing of all first-degree relatives. Every first-degree relative who tests positive requires the same management. This cascade has been documented to prevent deaths in relatives identified before their first clinical event. A missed diagnosis — a false-negative panel result that did not fully evaluate RYR2, CASQ2, or the CALM genes — delays all of these protective interventions until a cardiac arrest occurs.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Catecholaminergic Polymorphic Ventricular Tachycardia and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
